Optimal Examination Ways to follow up patients effected by COVID-19: case study in Jalawla General Hospital in Iraq



Human infections, Williamson


The period of survival of the Corona virus in the atmosphere for more than three hours does not reduce its possibility of infection, and in some surfaces such as stainless steel and plastic, the survival period reaches 72 hours. Currently, prevention methods must be followed due to the lack of effective treatment to avoid aggravating the situation, and one of the most important prevention methods is infection prevention and control (IPC), while Infection prevention and control (IPC) has led to a 30% reduction in infection rate in medical clinics and health care centres. The objective is to identify the most successful ways to follow up patients who had corona virus with the best drugs that are effective in a short period of time. To give a few examples of the ailments that fall under the category of chronic diseases: coronary heart disease, diabetes, high blood pressure, cancer, and asthma are just few of the diseases that fall into this category. In many cases, the symptoms of a chronic disease continue to be present for an extended period of time. During the course of this study endeavor, a sample of patients that is typical of the population was selected, and those patients were afterwards questioned about whether or not they suffered from a chronic ailment. The researchers have not only documented information on the history of the illness, but they have also documented other information regarding the patients, such as the patients' ages, genders, and current states of health. In addition, the researchers have documented information on the history of the illness.


Zumla, A., Chan, J. F., Azhar, E. I., Hui, D. S. and Yuen, K. Y. 2016. Coronaviruses drug discovery and therapeutic options. Nature Reviews Drug Discovery, 15(5): 327-347.

Gretebeck, L. M. and Subbarao, K. 2015. Animal models for SARS and MERS coronaviruses. Current Opinion in Virology, 13: 123-129.

Drosten, C., Günther, S., Preiser, W., Van Der Werf, S., Brodt, H. R., Becker, S. and Doerr, H. W. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New England Journal of Medicine, 348(20): 1967-1976.

Liu, J., Zheng, X., Tong, Q., Li, W., Wang, B., Sutter, K. and Yang, D. 2020. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. Journal of Medical Virology, 92(5): 491-494.

Lippi, G., Plebani, M. and Henry, B. M. 2020. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clinica. Chimica. Acta., 506: 145-148.

Ramírez-Truque, M. and Mauricio H. 2021. Rol Del Laboratorio Clínico Ante La Epidemia Del COVID-19: Revisión de Los Métodos Diagnósticos Disponibles y Sus Limitaciones.” Revista Médica de Costa Rica y Centroamérica 86(629): 73–80.

Letelier, P., Encina, N., Morales, P., Riffo, A., Silva, H., Riquelme, I. and Guzmán, N. 2021. Role of biochemical markers in the monitoring of COVID-19 patients. Journal of Medical Biochemistry, 40(2): 115.

Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H. and Li, F. 2020. Structural basis of receptor recognition by SARS-CoV-2. Nature, 581(7807): 221-224.

Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y. and Tian, D. S. 2020. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases, 71(15): 762-768.

Channappanavar, R. and Perlman, S. 2017. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. In Seminars in Immunopathology, 39(5): 529-539.

Chen, R., Sang, L., Jiang, M., Yang, Z., Jia, N., Fu, W. and for COVID, M. T. E. G. 2020. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. Journal of Allergy and Clinical Immunology, 146(1): 89-100.

Henry, B. M., De Oliveira, M. H. S., Benoit, S., Plebani, M. and Lippi, G. 2020. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM), 58(7): 1021-1028.

Mojtabavi, H., Saghazadeh, A. and Rezaei, N. 2020. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. European Cytokine Network, 31(2): 44-49.

Jurado, A., Martín, M. C., Abad-Molina, C., Orduña, A., Martínez, A., Ocaña, E. and Molina, J. 2020. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. Immunity and Ageing, 17(1): 1-15.

Zhou, Y., Guo, S., He, Y., Zuo, Q., Liu, D., Xiao, M. and Li, X. 2020. COVID-19 is distinct from SARS-CoV-2-negative community-acquired pneumonia. Frontiers in Cellular and Infection Microbiology, 10: 322.




How to Cite

MOHAMMED, H. A., Adem, Şevki, & SAHAB, K. S. (2023). Optimal Examination Ways to follow up patients effected by COVID-19: case study in Jalawla General Hospital in Iraq. IJASRaR, 1(1). Retrieved from https://ijasrar.com/index.php/ijasrar/article/view/5